key: cord-0074644-izbibpxz
authors: Dimopoulou, M; Komninaka, V; Flevari, P; Bartzi, V; Repa, K; Voskaridou, E
title: P111: COVID-19 IN PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: A SINGLE CENTER EXPERIENCE
date: 2022-01-31
journal: Hemasphere
DOI: 10.1097/01.hs9.0000821536.28990.38
sha: b1f1d439ef9b26f1938dbe826bd36da93190be55
doc_id: 74644
cord_uid: izbibpxz

nan

Introduction SCA is a common genetic disorder in Saudi Arabia with estimate of 1.4 % of population (1, 2) . The prevalence of SCD in Jazan region is around 24 per 10,000 which consider the second region with high prevalence of SCD after eastern province. COVID 19 infection outbreak has affected SCD with different outcome. Objectives: This research aims to determine the clinical picture of COVID-19 in patients with sickle cell disease SCD. The study represented the risk factors for severe COVID-19 presentation and predictors for poor prognosis in this group of patients. Methods: This study is a retrospective, descriptive, observational study of SCD adult and pediatric patients in Prince Mohammed Bin Nasser Hospital, Jazan, Saudi Arabia, who were diagnosed with COVID-19 virus infection at the study center from March 2020 to September 2021. To describe clinical presentation of SCD patients of different severities, who got COVID-19 during the study, socio-demographic data, clinical presentations, laboratory parameters, medications use, as well as COVID-19 symptoms and severity were extracted and analyzed from the medical record files. Results: 43 medical records for adult and pediatric sickle cell patients with COVID-19 were collected, in order to determine the impact of COVID-19 on the clinical presentation of SCD patients. (53%) were females, (47%) were males with a mean age of 24 years (±1.9). (37%) of the sample suffered from major comorbidities, out of which 44% had ACS. and 11.6% have pulmonary embolism. The most prevalent clinical symptoms were fever (56%) and Shortness of Breath (37%). (16%) of included patients were admitted to the ICU with an average length of stay equals to 3.9 days (±0.6). CBC showed normal averages of PLT with a mean equal to 327 K/uL (±21.6), Basophils 0.05 K/uL (±0.01), Lymphocytes 3.6 K/uL (±0.4). High averages were found for WBC 13.8 K/uL (±1.1), Neutrophils 8.8 K/uL (± 0.9) and PT 14.2 seconds (±0.3). The only laboratory parameter that showed low average reading was Hemoglobin, with a mean equal to 8 g/dl (±0.2). Out of the 41 patients who undergone CRP test, 85% were positive. The main CT chest finding were ground glass appearance in 30% of the patients 88% of the studied patients were on Hydroxyurea, 76% were on 1000 mg dose. For COVID-19 management, majority of patients were on Antibiotics 93%, 70% of patients started Anticoagulants, 51% of the patient has received antiviral treatment. 32.5% of the patient were treated with steroids. 70% of the patients have received blood transfusion. 5 patients 12% were managed at home. One patient had coinfection with falciparum malaria. Total deaths was 2 patients represented 4.6 % out of total SCD patients with COVID-19 who were included in the study.

After exploring the impact of COVID-19 on SCD patients, the main presenting symptom were fever and shortness of breath. The major complication were acute chest syndrome 44% and pulmonary embolism in 12%. The overall prognosis was excellent and most of the patient have recovered. The death was reported in 2 patients only. Outpatient treatments were feasible in 12% of the patients. Table 1 . None of the patient had cardiac iron overload, 2 had medium and 1 severe hepatic iron overload. Five patients had commorbidities (pulmonary hypertension 2, heart failure 1, atrial fibrillation 3, diabetes mellitus 2, arterial hypertension 1, malignant disease 1). Five patients had been vaccinated for COVID-19 before they presented with disease. The majority of patients (32/33) devepoped symptomatic disease of mild (26) or moderate (6) severity according to established criteria. Only one patient presented severe disease. Only 6/33 patients required hospitalization (4 thalassemic and 2 with SCD). In 4/6 hospitalized patients oxygen therapy with a nasal cannula was required and only one patient required a Venturi mask. None of the patients were intubated. One of the SCD patients developed an acute painful episode but there was no ACS post COVID-19. No increase in transfusion requirements was observed. There were no deaths in our patient population. All but one patients completely recovered whereas one SCD patient who was hospitalized is suffering from long-COVID. History of heart failure was associated with severe disease (p=0.03) and history of AF was associated with need for hospitalization (p=0.02). History of splenectomy, pulmonary hypertension or ACS and the degree of iron overload were not associated with disease severity or hospitalization requirement. Conclusion: COVID-19 had mild to moderate severity in the majority of our patients and only a minority of the patients required hospitalization. No ICU admissions or deaths were observed, comparing favourably to published data. Factors predisposing for severe COVID-19 in the general population, especially cardiac disease, seem to play a role also in patients with hemoglobinopathy. Background: Thalassemias are characterized by imbalanced globin-chain production resulting in excess α-or β-globin precipitation, hemolytic anemia, and ineffective erythropoiesis. 1,2 ATP levels are reduced in thalassemic red blood cells (RBCs), despite increased energy demands. 3, 4 Mitapivat is an oral activator of RBC pyruvate kinase (PKR), a glycolytic enzyme that regulates ATP production. 5 In a phase 2 study of patients with α-or β-non-transfusion-dependent thalassemia (NTDT), twicedaily (BID) dosing with mitapivat increased hemoglobin (Hb) levels by ≥1.0 g/dL in 80% of patients, 6 supporting the broadening of mitapivat's development in thalassemia. Aims: To report the study designs of ENERGIZE (2021-000211-23) and ENERGIZE-T (2021-000212-34) , two phase 3 trials to assess the efficacy and safety of mitapivat in adults with α-or β-NTDT or transfusion-dependent thalassemia (TDT), respectively. Methods: Both studies are phase 3, multicenter, randomized, double-blind, placebo-controlled trials (Figure) . In ENERGIZE, approximately 171 eligible adults with NTDT will be randomized (2:1) to receive 100 mg mitapivat BID or placebo for 24 weeks. Upon completion, eligible patients can transition to a 5-year, open-label extension. Key inclusion criteria: documented diagnosis of thalassemia (β-thalassemia ± α-globin mutations, Hb E β-thalassemia, or α-thalassemia [Hb H disease]), Hb concentration ≤10.0 g/dL, and NTDT defined as ≤5 RBC units during the 24-week period before randomization and no RBC transfusion ≤8 weeks prior. The primary endpoint is an Hb response defined as a ≥1.0 g/dL increase in average Hb concentration from Week 12 through 24 compared with baseline. Secondary endpoints include patient-reported outcomes, changes in Hb, markers of hemolysis and erythropoiesis, and safety. In ENERGIZE-T, approximately 240 eligible adults with TDT will be randomized (2:1) to receive 100 mg mitapivat BID or placebo for 48 weeks. Upon completion, eligible patients can transition to a 5-year, open-label extension. Key inclusion criteria: documented diagnosis of thalassemia (same genotypes as detailed for the ENERGIZE study), and TDT defined as 6-20 RBC units transfused and no transfusion-free period ≥6 weeks during the 24 weeks before randomization. The primary endpoint is a transfusion reduction response, defined as a ≥50% reduction in transfused RBC units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline. Secondary endpoints include additional measures of transfusion burden, changes in iron markers, and safety. Results: Not yet available. Conclusions: ENERGIZE and ENERGIZE-T are the first pivotal studies to assess a potential treatment across a broad spectrum of patients with thalassemia (ie, patients with TDT and NTDT; α-and β-thalassemias). ENERGIZE and ENERGIZE-T will evaluate the efficacy and safety of mitapivat, a novel, first-in-class oral activator of PKR. Both studies are actively recruiting.

TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND

Division of Hematology